Zox30 ml

Zox 30 ml is a broad-spectrum antiprotozoal medication primarily prescribed for the treatment of infectious diarrhea caused by specific parasitic organisms. It is clinically indicated for infections involving:

• Cryptosporidium parvum – a protozoan parasite responsible for cryptosporidiosis, which causes watery diarrhea, especially in immunocompromised patients and young children.
• Giardia lamblia – the causative organism of giardiasis, a common intestinal infection linked to contaminated food or water.
• Entamoeba histolytica – responsible for amoebic dysentery and intestinal amoebiasis.

Because of its activity against these organisms, Zox 30 ml is widely used in regions where waterborne and foodborne parasitic infections are common, including Bangladesh, as part of standard diarrheal disease management protocols.

Always take Zox 30 ml strictly according to a registered physician's advice.

Zox 30 ml belongs to the therapeutic class of Anti-diarrhoeal Antiprotozoal agents, used specifically to target and eliminate parasitic organisms responsible for infectious diarrhea.

Zox 30 ml is a synthetic, orally administered antiprotozoal agent belonging to the thiazolide class of drugs. Its therapeutic action centers on disrupting the energy metabolism of susceptible parasites.

Mechanism of Action

Zox 30 ml interferes with the pyruvate ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction. This biochemical pathway is essential for anaerobic energy production in protozoa. By blocking this reaction, Zox 30 ml effectively halts the parasite's ability to generate energy, leading to its death.

Active Metabolite

After absorption, Zox 30 ml is rapidly converted to its active metabolite, tizoxanide. Both the parent compound and tizoxanide demonstrate in vitro activity against:

• Sporozoites and oocysts of Cryptosporidium parvum
• Trophozoites of Giardia lamblia

This dual-action mechanism contributes to Zox 30 ml's effectiveness as a first-line treatment option for parasitic gastrointestinal infections.

Zox 30 ml is highly bound to plasma proteins, which means it has the potential to interact with other medications that share this same binding characteristic.

Plasma Protein Binding Interactions

Caution should be exercised when Zox 30 ml is co-administered with other highly plasma protein-bound drugs that have a narrow therapeutic index. In such cases, competition for protein-binding sites may alter the free (active) concentration of either drug, potentially increasing the risk of toxicity or reducing therapeutic effectiveness.

Patients on anticoagulants, anti-epileptics, or other narrow therapeutic index medications should inform their physician before starting Zox 30 ml, so appropriate monitoring or dose adjustment can be considered.

Like all medications, Zox 30 ml may cause side effects, though most are mild and resolve on their own.

Common Side Effects

• Abdominal pain
• Vomiting
• Headache

These effects are typically mild and transient in nature, meaning they usually subside without needing to stop treatment.

Rare Side Effects

• Nausea
• Loss of appetite (anorexia)
• Flatulence
• Increased appetite
• Enlarged salivary glands
• Elevated creatinine and SGPT (liver enzyme) levels
• Pruritus (itching)
• Rhinitis
• Excessive sweating
• Dizziness
• Discolored urine

Patients experiencing severe or persistent side effects should consult their physician promptly.

Pregnancy

Zox 30 ml falls under US FDA Pregnancy Category B. This indicates that animal reproduction studies have not demonstrated a risk to the fetus; however, there are no adequate and well-controlled studies conducted in pregnant women. Since animal studies do not always predict human response accurately, Zox 30 ml should only be used during pregnancy if clearly needed and under medical supervision.

Lactation

Zox 30 ml has been shown to be excreted in human breast milk. Therefore, caution is advised when administering this medication to breastfeeding mothers. A healthcare provider should evaluate the benefits versus potential risks before prescribing Zox 30 ml during lactation.

Zox 30 ml should be administered with caution in the following patient groups:

• Hepatic and biliary disease: Patients with liver or bile duct disorders require close monitoring, as Zox 30 ml metabolism may be affected.
• Renal disease: Patients with kidney impairment should be monitored carefully during treatment, as drug clearance may be altered.

Physicians should assess a patient's full medical history before prescribing Zox 30 ml to minimize the risk of adverse effects.

• Store in a dry place, away from direct light and heat.
• Keep the medication out of the reach of children.
• Do not use beyond the expiration date printed on the packaging.
• For oral suspension, check bottle-specific storage instructions (e.g., discard remaining suspension after a specified number of days once reconstituted).